NYSE : AGL

Agilon Health, Inc.

$129.79 USD

-$0.05 (-0.04%)

Volume
2.28K
Average Volume
416.51K
Market Capitalization
$2.17B
P/E Ratio
-5.72
Dividend Yield
0.00%
Price Target
$49.00
Year High
$133.04
Year Low
$7.48
Day High
Day Low
Payout Ratio
$0.00
Current Ratio
$1.04
Source Headline
agilon health Reports ACO REACH Model Results for 2024 Performance Year

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, announced that its Accountable Care Organizations (ACOs) achieved $229 million in gross savings (13.6% gross savings rate), including $54 million savings in the Medicare Trust Fund, during the 2024 performance year of the ACO Realizing Equity, Access and Community Health (ACO REACH) model. agilon's eight REACH ACOs operate under full risk, a.

businesswire.com - 2026-07-10 08:30:00

agilon health Sets Date to Report Second Quarter 2026 Financial Results

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that it will release financial results for the second quarter 2026 after market close on Wednesday, August 5, 2026 and host a conference call at 4:30 p.m. ET to discuss the results. The conference call can be accessed by dialing (833) 439-1904 for U.S. participants and +1 (585) 542-9983 for international participants and refe.

businesswire.com - 2026-07-07 16:05:00

Agilon Health (AGL) Is Up 0.79% in One Week: What You Should Know

Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-06-26 13:00:51

Why Fast-paced Mover Agilon (AGL) Is a Great Choice for Value Investors

If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Agilon (AGL) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

zacks.com - 2026-06-26 09:56:10

agilon health: Q1 Inflection And A New CEO Set Up A Multi-Year Rerating

agilon health is rated Buy with a $177 price target, reflecting a robust Q1 beat and a positive inflection in financials. Q1 2026 delivered $1.42B revenue (+$40M vs. consensus), $54M adjusted EBITDA (+162% YoY), and raised full-year guidance across all key metrics. Margin expansion is driven by a new data pipeline, scaled clinical programs, disciplined payer contracting, and AI-driven risk scoring now fully operational.

seekingalpha.com - 2026-06-24 02:40:56

Is the Options Market Predicting a Spike in agilon health Stock?

Investors need to pay close attention to AGL stock based on the movements in the options market lately.

zacks.com - 2026-06-23 10:26:01

agilon health to Participate in Upcoming Conferences

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced that members of its management team will participate in investor meetings and industry discussions at the following conferences: Truist Securities Healthcare Disruptors & Digital Health Conference on Tuesday, June 23, 2026 in New York. Management will participate in an ACO Model panel discussion at 1:50pm ET and conduct o.

businesswire.com - 2026-06-09 16:05:00

These ETFs Owned Russell 2000's Biggest Winners Before They Soared 400%+ In 2026

Investors searching for the biggest stock winners of 2026 may be surprised to learn they already own some of them through small-cap ETFs.

benzinga.com - 2026-06-03 14:54:10

Are You Looking for a Top Momentum Pick? Why Agilon Health (AGL) is a Great Choice

Does Agilon Health (AGL) have what it takes to be a top stock pick for momentum investors? Let's find out.

zacks.com - 2026-05-28 13:01:17

Are Medical Stocks Lagging Agilon Health (AGL) This Year?

Here is how Agilon Health (AGL) and Humacyte, Inc. (HUMA) have performed compared to their sector so far this year.

zacks.com - 2026-05-27 10:40:24

Despite Fast-paced Momentum, Agilon (AGL) Is Still a Bargain Stock

Agilon (AGL) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

zacks.com - 2026-05-27 09:55:45

Is Agilon Health (AGL) Stock Outpacing Its Medical Peers This Year?

Here is how Agilon Health (AGL) and Amarin (AMRN) have performed compared to their sector so far this year.

zacks.com - 2026-05-11 10:40:47

Agilon (AGL) Is Attractively Priced Despite Fast-paced Momentum

Agilon (AGL) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.

zacks.com - 2026-05-11 09:55:24

Agilon Health Is Up 115% After Earnings. Why the Stock Is Having Its Best Day Ever.

Shares of Agilon Health cratered in 2025, driven by financial underperformance and a guidance suspension.

barrons.com - 2026-05-07 12:51:00

Agilon Health Operational Initiatives Begin Showing Results

Agilon Health Inc. (NYSE:AGL) shares are soaring on Thursday as the company recently announced an increase in its full-year 2026 guidance. The company operates and manages a network of independent physicians.

benzinga.com - 2026-05-07 11:49:46

agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript

agilon health, inc. (AGL) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 23:01:14

Agilon Health (AGL) Q1 Earnings and Revenues Top Estimates

Agilon Health (AGL) came out with quarterly earnings of $1.8 per share, beating the Zacks Consensus Estimate of $1.13 per share. This compares to break-even earnings per share a year ago.

zacks.com - 2026-05-06 19:35:54

Agilon (AGL) Reports Q1 Earnings: What Key Metrics Have to Say

The headline numbers for Agilon (AGL) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

zacks.com - 2026-05-06 19:01:11

agilon health Reports First Quarter 2026 Results

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to transform health care in our communities, today announced results for the first quarter ended March 31, 2026. In addition, the company increased full-year 2026 guidance for total revenues, medical margin, and Adjusted EBITDA. “Our strong first-quarter performance and increase in full-year 2026 guidance reflects disciplined execution and progress against our strategic priorities. We.

businesswire.com - 2026-05-06 16:05:00

Australia's AGL Energy lifts lower end of fiscal 2026 earnings outlook

Australia's AGL Energy on Wednesday ​raised the lower ‌end of its full-year profit forecast, ​helped by ​the continued strong operational ⁠and financial ​performance of its ​business since its last update in February.

reuters.com - 2026-05-05 18:48:17

agilon health Appoints Tim O'Rourke as Chief Executive Officer

WESTERVILLE, Ohio--(BUSINESS WIRE)--agilon health (NYSE: AGL) (the “Company”), the trusted partner empowering physicians to transform health care in our communities, today announced the appointment of Tim O'Rourke as Chief Executive Officer and a member of the Company's Board of Directors, effective May 7. He succeeds Ronald A. Williams, who has served as Executive Chairman since August 2025 and will continue as Chairman of the Board. The appointment comes as agilon enters a new phase following.

businesswire.com - 2026-04-27 16:15:00

Is Agilon Health (AGL) Outperforming Other Medical Stocks This Year?

Here is how Agilon Health (AGL) and Caribou Biosciences, Inc. (CRBU) have performed compared to their sector so far this year.

zacks.com - 2026-04-21 10:41:27

agilon health's Vitals Are Improving (Upgrade)

agilon health is rated a cautious 'Hold' as management executes a strategic downsizing to address persistent losses. Recent exits from underperforming markets and partnerships are expected to improve medical margin from -$56.6 million in 2025 to $325 million in 2026. Despite revenue and membership declines, AGL guides for near break-even EBITDA in 2026, a significant improvement from -$296.2 million prior.

seekingalpha.com - 2026-04-20 12:59:34

Get AGL Insider Trade Alerts

AGL Price Target Summary

Last Month

$141.00

1 analysts

Last Quarter

$78.20

5 analysts

Last Year

$56.11

9 analysts

All Time

$125.33

15 analysts

AGL Recent Analyst Grades

Date Analyst Firm Action Previous Grade New Grade
2026-07-13 Wells Fargo Maintain Overweight Overweight
2026-05-26 Barclays Upgrade Underweight Equal Weight
2026-05-21 Benchmark Maintain Buy Buy
2026-05-15 Citigroup Maintain Neutral Neutral
2026-05-11 TD Cowen Maintain Hold Hold
2026-05-08 Wells Fargo Maintain Overweight Overweight
2026-05-07 Jefferies Upgrade Hold Buy
2026-05-07 Baird Maintain Neutral Neutral
2026-05-07 Evercore ISI Group Maintain In Line In Line
2026-05-07 Deutsche Bank Upgrade Hold Buy
2026-05-04 JP Morgan Downgrade Neutral Underweight
2026-04-02 Benchmark Maintain Buy Buy
2026-03-03 Citigroup Maintain Neutral Neutral
2026-02-27 Wells Fargo Maintain Overweight Overweight
2026-02-27 Barclays Maintain Underweight Underweight
2025-11-06 Barclays Maintain Underweight Underweight
2025-11-05 Wells Fargo Maintain Overweight Overweight
2025-10-07 Wells Fargo Maintain Overweight Overweight
2025-08-20 Bernstein Downgrade Outperform Market Perform
2025-08-15 Jefferies Maintain Hold Hold
2025-08-14 Baird Maintain Neutral Neutral
2025-08-06 Barclays Maintain Underweight Underweight
2025-08-06 Benchmark Maintain Buy Buy
2025-08-06 Citigroup Downgrade Buy Neutral
2025-07-09 Evercore ISI Group Maintain In Line In Line
2025-05-29 Bernstein Maintain Outperform Outperform
2025-05-13 Wells Fargo Maintain Overweight Overweight
2025-05-08 Goldman Sachs Maintain Neutral Neutral
2025-05-08 Barclays Maintain Underweight Underweight
2025-04-28 JMP Securities Maintain Market Perform Market Perform
2025-04-25 Citigroup Upgrade Neutral Buy
2025-04-15 TD Cowen Maintain Hold Hold
2025-04-15 Baird Maintain Neutral Neutral
2025-04-08 Bernstein Upgrade Market Perform Outperform
2025-04-08 Wells Fargo Maintain Overweight Overweight
2025-03-21 Needham Maintain Hold Hold
2025-02-26 Stifel Maintain Hold Hold
2025-02-26 Needham Maintain Hold Hold
2025-02-26 RBC Capital Maintain Outperform Outperform
2025-02-26 Citizens Capital Markets Maintain Market Perform Market Perform
2025-01-15 Bernstein Maintain Market Perform Market Perform
2025-01-10 Needham Maintain Hold Hold
2025-01-10 Citigroup Upgrade Sell Neutral
2024-11-19 RBC Capital Maintain Outperform Outperform
2024-11-13 Citigroup Maintain Sell Sell
2024-11-12 Stifel Maintain Hold Hold
2024-11-11 Barclays Maintain Underweight Underweight
2024-11-11 JMP Securities Downgrade Market Outperform Market Perform
2024-11-11 TD Cowen Maintain Hold Hold
2024-11-08 William Blair Downgrade Outperform Market Perform
2024-10-29 Citigroup Downgrade Neutral Sell
2024-10-08 Evercore ISI Group Maintain In Line In Line
2024-10-02 B of A Securities Downgrade Buy Underperform
2024-08-09 Deutsche Bank Maintain Hold Hold
2024-08-08 Benchmark Maintain Buy Buy
2024-08-07 RBC Capital Maintain Outperform Outperform
2024-07-09 Evercore ISI Group Maintain In Line In Line
2024-05-24 Truist Securities Maintain Hold Hold
2024-05-01 Stifel Maintain Hold Hold
2024-04-15 Truist Securities Maintain Hold Hold
2024-02-29 Truist Securities Maintain Hold Hold
2024-02-29 Benchmark Maintain Buy Buy
2024-02-28 Evercore ISI Group Maintain In Line In Line
2024-02-28 RBC Capital Maintain Outperform Outperform
2024-02-26 TD Cowen Downgrade Outperform Market Perform
2024-02-22 Stifel Maintain Hold Hold
2024-01-08 Wolfe Research Downgrade Outperform Peer Perform
2024-01-05 Truist Securities Downgrade Buy Hold
2024-01-05 JP Morgan Downgrade Overweight Neutral
2023-12-11 Goldman Sachs Downgrade Buy Neutral
2023-11-21 Deutsche Bank Downgrade Buy Hold
2023-11-15 Benchmark Maintain Buy Buy
2023-11-13 Wells Fargo Maintain Overweight Overweight
2023-11-09 Goldman Sachs Maintain Buy Buy
2023-11-09 Truist Securities Maintain Buy Buy
2023-11-03 RBC Capital Maintain Outperform Outperform
2023-08-15 Goldman Sachs Maintain Buy Buy
2023-08-15 TD Cowen Maintain Outperform Outperform
2023-06-20 Truist Securities Maintain Buy Buy
2023-06-13 Deutsche Bank Maintain Buy Buy
2023-05-31 Goldman Sachs Maintain Buy Buy
2023-05-15 Deutsche Bank Maintain Buy Buy
2023-05-10 Stifel Maintain Buy Buy
2023-05-10 RBC Capital Maintain Outperform Outperform
2023-04-17 Truist Securities Maintain Buy Buy
2023-03-06 Guggenheim Maintain Buy Buy
2023-03-03 Deutsche Bank Maintain Buy Buy
2022-12-09 Stifel Maintain Buy Buy
2022-11-15 Goldman Sachs Maintain Buy Buy
2022-11-15 Wells Fargo Maintain Overweight Overweight
2022-11-04 SVB Leerink Maintain Outperform Outperform
2022-09-14 RBC Capital Maintain Outperform Outperform
2022-09-12 Goldman Sachs Maintain Buy Buy
2022-08-08 Wells Fargo Maintain Overweight Overweight
2022-08-03 Deutsche Bank Maintain Buy Buy
2022-07-14 Truist Securities Maintain Buy Buy
2022-06-24 BTIG Maintain Neutral Neutral
2022-06-08 Deutsche Bank Maintain Buy Buy
2022-05-10 Deutsche Bank Maintain Buy Buy
2022-03-31 SVB Leerink Maintain Outperform Outperform
2022-03-30 Guggenheim Maintain Buy Buy
2022-03-15 SVB Leerink Maintain Outperform Outperform
2022-03-06 Deutsche Bank Maintain Buy Buy
2022-01-25 Deutsche Bank Maintain Buy Buy
2021-12-14 Deutsche Bank Maintain Buy Buy
2021-11-03 Deutsche Bank Maintain Buy Buy
2021-11-01 SVB Leerink Maintain Outperform Outperform
2021-10-20 Jefferies Maintain Buy Buy
2021-09-27 SVB Leerink Maintain Outperform Outperform
2021-09-10 Cowen & Co. Maintain Outperform Outperform
2021-08-06 Deutsche Bank Maintain Buy Buy
2021-06-03 Wells Fargo Maintain Overweight Overweight
2021-05-28 Deutsche Bank Maintain Buy Buy
2021-05-11 William Blair Maintain Outperform Outperform
2021-05-10 Deutsche Bank Maintain Buy Buy
2021-05-10 JP Morgan Maintain Overweight Overweight